Breaking News for Investors: Jazz Pharmaceuticals is gearing up to participate in Citi's 2025 Global Healthcare Conference! This is a significant event, and here's what you need to know.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has announced its involvement in the highly anticipated Citi's 2025 Global Healthcare Conference. This presents a prime opportunity for the company to connect with investors and share insights. Company management will be participating in a fireside chat, a less formal interview setting designed to foster open discussion, on Tuesday, December 2, 2025.
But here's the crucial part: the fireside chat will kick off at 6:45 a.m. PST, which translates to 9:45 a.m. EST, or 2:45 p.m. GMT. Make sure you mark your calendars accordingly to catch the discussion live!
For those unable to attend in person, don't worry! An audio webcast of the fireside chat will be readily available. You can access it through the Investors section of the Jazz Pharmaceuticals website. A replay of the webcast will also be archived on the website for a generous 30 days, giving you ample time to catch up on the key takeaways.
What is Jazz Pharmaceuticals?
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharmaceutical company with a mission to improve the lives of patients and their families through innovation. They focus on developing life-changing medicines, particularly for those with serious diseases where treatment options are limited or nonexistent. Their current portfolio includes leading therapies for sleep disorders and epilepsy, as well as a growing selection of cancer treatments. Jazz Pharmaceuticals is committed to research and development, with a robust pipeline of innovative treatments in oncology and neuroscience. The company is headquartered in Dublin, Ireland, and has research, development, and manufacturing facilities across multiple countries.
Contact Information:
For any investor-related inquiries, you can reach out to Jack Spinks, Executive Director of Investor Relations, at InvestorInfo@jazzpharma.com or by phone at +353 1 634 3211 (Ireland) or +1 650 496 2717 (U.S.).
For media inquiries, contact Kristin Bhavnani, Head of Global Corporate Communications, at CorporateAffairsMediaInfo@jazzpharma.com, or call +353 1 637 2141 (Ireland) or +1 215 867 4948 (U.S.).
Final Thoughts:
This conference participation underscores Jazz Pharmaceuticals' commitment to transparency and communication with its stakeholders. What are your thoughts on this announcement? Do you think this will have a positive impact on the company's stock? Share your opinions in the comments below!
